Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial

American Journal of Transplantation

Volumn 17, Issue 3, 2017, Pages 682-691

  Kulkarni, S ^a   Kirkiles Smith, N C ^a   Deng, Y H ^b   Formica, R N ^a   Moeckel, G ^a   Broecker, V ^c   Bow, L ^a   Tomlin, R ^a   Pober, J S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

alloantibody; basic (laboratory) research science; chronic allograft nephropathy; clinical research practice; clinical trial; complement biology; kidney failure injury; kidney transplantation nephrology

Indexed keywords

CD31 ANTIGEN; COMPLEMENT COMPONENT C1Q; ECULIZUMAB; PALMD PROTEIN; PROTEIN; SELE PROTEIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; ALLOANTIBODY; COMPLEMENT COMPONENT C5; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ANTIBODY MEDIATED REJECTION; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPLEMENT INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; MALE; PARALLEL DESIGN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION; VIRUS INFECTION; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; DONOR; DRUG EFFECTS; EARLY CHILDHOOD INTERVENTION; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; LIVING DONOR; MIDDLE AGED; PROGNOSIS; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC DISEASE; COMPLEMENT C5; COMPLEMENT INACTIVATING AGENTS; EARLY INTERVENTION (EDUCATION); FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; RISK FACTORS; TISSUE DONORS; TRANSPLANT RECIPIENTS; YOUNG ADULT;

EID: 84987877226     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.14001     Document Type: Article

References (25)

1. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270: 1339–1343.
2. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235–242.
3. Heaphy EL, Poggio ED, Flechner SM, et al. Risk factors for retransplant kidney recipients: Relisting and outcomes from patients’ primary transplant. Am J Transplant 2014; 14: 1356–1367.
4. Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2014 Annual Data Report: Kidney. Am J Transplant 2016; 16(Suppl 2): 11–46.
5. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665–673.
6. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532–2541.
7. Halloran PF, Pereira AB, Chang J, et al. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: An international prospective study (INTERCOM). Am J Transplant 2013; 13: 2865–2874.
8. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215–1226.
9. Halloran PF, Reeve JP, Pereira AB, Hidalgo LG, Famulski KS. Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: New insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int 2014; 85: 258–264.
10. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant 2015; 15: 2921–2930.
11. Valenzuela NM, McNamara JT, Reed EF. Antibody-mediated graft injury: Complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant 2014; 19: 33–40.
12. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398–1406.
13. Lefaucheur C, Viglietti D, Bentlejewski C, et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 2016; 27: 293–304.
14. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157–1167.
15. Duquesnoy RJ, Marrari M, Jelenik L, Zeevi A, Claas FH, Mulder A. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays. Hum Immunol 2013; 74: 1271–1279.
16. Bohmig GA, Bartel G, Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant 2008; 13: 411–418.
17. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56–65.
18. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312–2323.
19. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: A simulation study. BMC Med Res Methodol 2001; 1: 6.
20. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464–470.
21. Sis B, Mengel M, Haas M, et al. Banff ‘09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464–471.
22. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033–1041.
23. Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013; 95: 1113–1119.
24. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012; 94: 172–177.
25. DeVos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598–604.